Baseline Serum Cholesterol Levels Predict the Response of Patients with Advanced Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitor-Based Treatment

Baseline Serum Cholesterol Levels Predict the Response of Patients with Advanced Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitor-Based Treatment

Jingtao Tong III,1,* Yifei Mao,2,* Ziru Yang,1 Quan Xu,1 Zhen Zheng,1 Hui Zhang,1 Jingjing Wang,1 Sandian Zhang,1 Weibo Rong,3 Lu Zheng III1 1Department of Radiation Oncology, Ningbo Medical Treatment Center Li Huili Hospital, Ningbo, 315040, People’s Republic of China; 2Department of Emer...

Full description

Bibliographic Details
Main Authors: Tong III J, Mao Y, Yang Z, Xu Q, Zheng Z, Zhang H, Wang J, Zhang S, Rong W, Zheng III L
Format: Article
Language:English
Published: Dove Medical Press 2021-05-01
Series:Cancer Management and Research
Subjects:
non-small cell lung cancer
nsclc
serum cholesterol
immune checkpoint inhibitors
icis
prognostic marker
Online Access:https://www.dovepress.com/baseline-serum-cholesterol-levels-predict-the-response-of-patients-wit-peer-reviewed-fulltext-article-CMAR

Internet

https://www.dovepress.com/baseline-serum-cholesterol-levels-predict-the-response-of-patients-wit-peer-reviewed-fulltext-article-CMAR

Similar Items